. "71" . . . "Skalick\u00E1, Anna" . "Serum Immunoglobulin Free Light Chains in Severe Forms of Atopic Dermatitis" . . . "0300-9475" . "Serum Immunoglobulin Free Light Chains in Severe Forms of Atopic Dermatitis" . . "RIV/00064203:_____/10:6213!RIV11-MZ0-00064203" . . "RIV/00064203:_____/10:6213" . "Polou\u010Dkov\u00E1, Andrea" . . "Serum Immunoglobulin Free Light Chains in Severe Forms of Atopic Dermatitis"@en . "000275918400012" . "287029" . . "I, S, Z(MSM0021620812), Z(MZ0FNM2005)" . . . . . "[4233E2772B7D]" . . "Kayserov\u00E1, Jana" . . "\u010Capkov\u00E1, \u0160t\u011Bp\u00E1nka" . . "Malinova, V." . "inflammatory diseases; ig; immediate; responses; allergy; marker; target; urine; cells"@en . "Vernerov\u00E1, Eva" . "Bart\u016F\u0148kov\u00E1, Ji\u0159ina" . . "8"^^ . "NO - Norsk\u00E9 kr\u00E1lovstv\u00ED" . "7"^^ . . . . . . . . "Scandinavian Journal of Immunology" . "An increase in immunoglobulin free light chains (FLC) was recently described in several pathological conditions, including asthma. FLC pathology is classically associated with monoclonal gammopathies. Its association with allergic disorders is surprising and unexplained. We therefore tested a cohort of children with severe atopic dermatitis (SCORAD 50-80) to determine the serum levels of free kappa and lambda chains, and correlated the results with clinical status and relevant laboratory markers. Seventy-three patients with severe forms of AD, all children from 3 months to 3 years of age and ninety healthy age-matched controls were included in the study."@en . "5"^^ . . "Serum Immunoglobulin Free Light Chains in Severe Forms of Atopic Dermatitis"@en . "\u0160ediv\u00E1, Anna" . "4" . . . . "An increase in immunoglobulin free light chains (FLC) was recently described in several pathological conditions, including asthma. FLC pathology is classically associated with monoclonal gammopathies. Its association with allergic disorders is surprising and unexplained. We therefore tested a cohort of children with severe atopic dermatitis (SCORAD 50-80) to determine the serum levels of free kappa and lambda chains, and correlated the results with clinical status and relevant laboratory markers. Seventy-three patients with severe forms of AD, all children from 3 months to 3 years of age and ninety healthy age-matched controls were included in the study." . . .